Chatterjee, Suparna  <br/><br/>
Update of antispike severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) monoclonal antibodies 

 - Vol.54(1), Jan-Feb 
 - Mumbai  Wolter Kluwer  2022 
 - 51-57p. 
<br/><br/> The use of monoclonal antibodies has expanded beyond the realm of autoimmune disease and cancer<br/>therapeutics to communicable diseases. Their antiviral activities were evaluated in some diseases<br/>such as SARS MERS (Middle East Respiratory Syndrome) and Ebola. In recent times, antispike<br/>SARS‑CoV‑2 monoclonal antibody cocktails (casirivimab with imdevimab and bamlanivimab with<br/>etesevimab) and single agent sotrovimab have received emergency use authorization for treatment of<br/>nonhospitalized COVID‑19 patients with mild‑to‑moderate disease at high risk of disease progression.<br/>This review summarizes their mechanism of action, salient pharmacokinetic profile, safety and clinical<br/>trial (ongoing and completed) data. Despite evidence to support its use for the indication, the high<br/>cost of these biologics may make it unaffordable for many patients, but further clinical studies on<br/>their cost‑benefit profile shall provide useful information to the scientific community and patients. 
<br/><br/><label>Subjects--Topical Terms: </label><br/>PHARMACOLOGY